| Sublocade (buprenorphine once-monthly depot) / Indivior |
NCT05704543: Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations |
|
|
| Completed | 4 | 88 | US | Buprenorphine Extended-Release Injection, SUBLOCADE® | Indivior Inc. | Opioid Use Disorder | 11/23 | 11/23 | | |
STOPIT, NCT05594121: Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder |
|
|
| Not yet recruiting | 4 | 90 | Canada | Extended Release Subcutaneous Buprenorphine, Sublocade, Immediate Release Sublingual Buprenorphine, Suboxone | Royal Victoria Hospital, Canada | Moderate to Severe Opioid Use Disorder | 12/23 | 12/24 | | |
| Completed | 4 | 785 | Canada, US | Transmucosal Buprenorphine, Extended-release Buprenorphine, RBP-6000, SUBLOCADE | Indivior Inc. | Moderate to Severe Opioid-use Disorder | 06/24 | 06/24 | | |
NCT04219540: Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults |
|
|
| Recruiting | 4 | 796 | US | XR-B (SUBLOCADETM), SUBLOCADE TM, XR-NTX, Vivitrol® | NYU Langone Health, National Institute on Drug Abuse (NIDA) | Opioid-use Disorder | 06/24 | 12/24 | | |
NCT06051890: Assessing Optimal XRB Initiation Points in Jail |
|
|
| Not yet recruiting | 4 | 200 | US | Extended-Release Buprenorphine (XRB), Sublocade, Sublingual Buprenorphine (SLB) | NYU Langone Health, National Institute on Drug Abuse (NIDA) | Opioid Use Disorder | 06/26 | 10/26 | | |
NCT05481112: Assessing Optimal XR-Buprenorphine Initiation Points in Jail |
|
|
| Withdrawn | 4 | 200 | US | Extended-Release Buprenorphine Injection, Sublocade | NYU Langone Health, National Institute on Drug Abuse (NIDA) | Opioid Use Disorder | 11/25 | 02/26 | | |
2018-004460-63: Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO) |
|
|
| Not yet recruiting | 3 | 600 | Europe | Sublocade, Buprenorphine, METHADONE, Buprenorphine-Naloxone, Espranor Oral lyophilisate, RBP-6000, Solution for infusion in pre-filled syringe, Sublingual tablet, Oral liquid, Oral lyophilisate, SUBOXONE, Espranor | South London and Maudsley NHS Foundation Trust, King's College London, INDIVIOR UK | Opiod addiction, Opiod Addiction, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Completed | 3 | 342 | Europe | Buprenorphine Injectable Product, Sublocade®; prev. RBP-60000, Methadone, Buprenorphine, Suboxone, Espranor, Subutex | King's College London, South London and Maudsley NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, Cumbria, Northumberland Tyne and Wear NHS Foundation Trust, Birmingham and Solihull Mental Health NHS Foundation Trust, NHS Tayside, Bangor University | Opiate Substitution Treatment | 04/22 | 03/23 | | |
NCT04352166: Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder |
|
|
| Suspended | 2 | 40 | US | extended-release buprenorphine (BXR), Sublocade, sublingual buprenorphine (BSL), buprenorphine | New York State Psychiatric Institute, National Institute on Drug Abuse (NIDA) | Opioid-use Disorder | 12/24 | 12/24 | | |
BOPAT, NCT04677114: Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections |
|
|
| Recruiting | 2 | 90 | US | Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Suboxone or Sublocade, Buprenorphine and standard of care antibiotic treatment | Laura Fanucchi, National Institute on Drug Abuse (NIDA) | Drug Use, Opioid-use Disorder | 05/25 | 08/25 | | |
| Recruiting | 2 | 122 | US | INDV-6001, Suboxone, Sublocade | Indivior Inc. | Moderate to Severe Opioid Use Disorder | 10/25 | 10/25 | | |
| Terminated | 2 | 18 | US | Buprenorphine injection (BUP-Inj), SublocadeTM, Indivior, Placebo injection, Placebo injection (PBO-Inj) | Madhukar H. Trivedi, MD | Methamphetamine-dependence | 10/23 | 11/23 | | |
| Recruiting | 1 | 40 | US | Combined LAI Treatment: Cabenuva and Sublocade, rilpivirine (CAB/RPV) "cabenuva", extended-release buprenorphine (XR-B) "sublocade" | Rhode Island Hospital | Human Immunodeficiency Virus, Opioid Use Disorder | 04/24 | 10/24 | | |
NCT05878210: Evaluating the SUBLOCADE Treatment Exit Strategy |
|
|
| Recruiting | N/A | 25 | Canada, US | | Indivior Inc. | Opioid Use Disorder | 05/25 | 05/25 | | |
| Recruiting | N/A | 1200 | Europe, Canada, US, RoW | | Indivior Inc. | Opioid Use Disorder | 08/27 | 08/27 | | |
